Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies

Aviv Ladanie; Benjamin Speich; Matthias Briel; Francesco Sclafani; Heiner C. Bucher; Arnav Agarwal; John P A Ioannidis; Tiago Pereira; Benjamin Kasenda; Lars G. Hemkens

doi:10.1016/j.jclinepi.2019.05.033

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Preprint2020

FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)

Kim Boesen, Peter C Gøtzsche, John P A Ioannidis

Article2020

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

Aviv Ladanie, Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago Pereira, Francesco Sclafani, Amanda K. Herbrand, Matthias Briel, Juan Martín-Liberal, Thomas Schmid, Hannah Ewald, John P A Ioannidis, Heiner C. Bucher, Benjamin Kasenda, Lars G. Hemkens

Article2025

FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer

Oliver Kepp, Guido Guido Kroemer

Article2026

Reply to Beyond binary classification of non-proportional hazards: methodological considerations for interpreting pivotal HCC trials

Ezequiel Mauro, Amit Singal, Josep M. Llovet

Article2018

The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics.

Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Timothy Akhurst, Aravind Ravi Kumar, Grace Kong, Scott Williams, Rodney J. Hicks, Michael S. Hofman